Gold X2 Mining Inc. (TSXV: AUXX) (OTCQB: GSHRF) (FSE: DF8) (“Gold X2” or the “Company”) is pleased to announce a significant update ...

Strategic process -- Formal engagement with Evercore concluded; current focus is on Phase III clinical execution, with ...

Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; ...

Nebius Group N.V. sees strong AI growth and a $3B Meta deal, yet shares dip. Click for my updated look at NBIS stock ...

November 18, 2025) - Adyton Resources Corporation (TSXV: ADY) (" Adyton " or the " Company ") is pleased to announce that its ...

Explore why power projects face chronic cost and schedule overruns and how digital tools, modular construction, and real-time ...

Bletchley Park was more than a place — it was a method. During World War II, the United Kingdom combined science, engineering ...

Topline results that were recently released from Sydnexis’s phase 3 Study of Atropine for the Reduction of Myopia Progression (STAR) trial of SYD-101 (atropine 0.01%) for slowing the progression of ...

-- 63% complete response (CR) rate at any time (n=62); -- 56% CR rate at 3 months (n=62); -- 62% CR rate at 6 months (n=37), with 4 patients having successfully converted to CR post reinduction; and - ...

Broadcast Retirement Network's Jeffrey Snyder discusses how to prevent cardiovascular disease at any age with Cone Health's ...

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and nine ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...